4CPS-040 Cost-comparison of secukinumab and ustekinumab for treatment of psoriasis

BACKGROUND: Secukinumab is a monoclonal antibody designed to recognise and attach to a messenger molecule in the immune system called interleukin 17A, whereas ustekinumab is also a monoclonal antibody which attaches to two cytokines called interleukin 12 and interleukin 23. All these cytokines are i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Eur J Hosp Pharm
Glavni autori: Gonzalez, M Suarez, Melini, E Gomez, Ruiz, P Diaz, Santana, E Ramos, Garcia, I Plasencia, Rojas, S Hernandez, Gomez, MA Ocaña, Alonso, J Merino
Format: Artigo
Jezik:Inglês
Izdano: BMJ Group 2018
Teme:
Section 4: Clinical pharmacy services
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535608/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.131
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items